1. P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA. (5th April 2022) Authors: Usmani, S; Alonso, A; Quach, H; Koh, Y; Guenther, A; Min, CK; Leleu, X; Abdallah, AO; Oriol, A; Bessemer, B; Garg, M; Sandhu, I; Weisel, K; Ocio San Miguel, E; Cavo, M; Zhou, X; Kaisermann, M; Mis, L; Williams, D; Yeakey, A Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗